Advertisement

Topics

The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing

02:35 EST 9 Nov 2017 | Forbes

Meanwell believes that inclisiran can be a very successful drug at a much lower price than Repatha and Praluent.

Original Article: The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing

NEXT ARTICLE

More From BioPortfolio on "The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...